[February 03, 2016]

ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC (News - Alert)) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• Leerink Partners 5^th Annual Global Healthcare Conference
  2:40 pm ET, February 10

• RBC Capital Markets Global Healthcare Conference
  11:30 am ET, February 23
• Cowen and Company 36^th Annual Health Care Conference
  9:20 am ET, March 8




The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.




ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor a-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla^®. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.



View source version on businesswire.com: http://www.businesswire.com/news/home/20160203005095/en/




[ Back To TMCnet.com's Homepage ]